文献速递艾滋病与性传播感染

他莫昔芬对接受抗逆转录病毒治疗的女性中伏立诺他诱导的HIV表达的影响:AIDS临床试验组A5366,MOXIE试验

Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
PubMed 文献 · Clin Infect Dis · 2022-01-01

AIDS临床试验组A5366将31名病毒学抑制的绝经后女性按2:1随机分配接受他莫昔芬联合伏立诺他或仅观察后伏立诺他,主要终点为安全性和伏立诺他后HIV RNA诱导的组间差异。他莫昔芬未增强伏立诺他诱导的HIV转录(组间比值0.8;95%CI 0.2-2.4),未归因于研究治疗的显著不良事件。

要点

  • 他莫昔芬未增强伏立诺他诱导的HIV转录,组间比值0.8(95%CI 0.2-2.4)。
  • 伏立诺他诱导的HIV转录在H4Ac增加者中较高(倍数增加2.78;95%CI 1.34-5.79),未增加者为1.04(95%CI 0.25-4.29)。
  • HIV DNA和单拷贝法血浆病毒血症无实质性变化。

核心结论

  • 他莫昔芬未增强绝经后女性中伏立诺他诱导的HIV RNA表达。
  • 伏立诺他适度的潜伏逆转活性、绝经后状态和接近定量下限的低水平HIV RNA表达限制了他莫昔芬影响的评估。
  • 本研究是首个仅在女性中进行的HIV治愈试验,确立了在感染HIV女性中研究新型HIV治愈策略的可行性和必要性。

研究设计与样本

  • AIDS临床试验组A5366纳入31名病毒学抑制的绝经后女性,接受抗逆转录病毒治疗。
  • 参与者按2:1随机分配接受他莫昔芬(A组,TAMOX/VOR)或观察(B组,VOR)5周,随后接受2剂伏立诺他。
  • 主要终点为安全性和伏立诺他后HIV RNA诱导的组间差异。
  • 次要分析包括组蛋白4乙酰化、HIV DNA和单拷贝法血浆病毒血症。

主要发现

  • 无归因于研究治疗的显著不良事件。
  • 他莫昔芬未增强伏立诺他诱导的HIV转录(组间比值0.8;95%CI 0.2-2.4)。
  • 伏立诺他诱导的HIV转录在H4Ac增加者中较高(倍数增加2.78;95%CI 1.34-5.79),未增加者为1.04(95%CI 0.25-4.29)。
  • HIV DNA和单拷贝法血浆病毒血症无实质性变化。

局限性

  • 伏立诺他适度的潜伏逆转活性、绝经后状态和接近定量下限的低水平HIV RNA表达限制了他莫昔芬影响的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological sex and the estrogen receptor alpha (ESR1) modulate human immunodeficiency virus (HIV) activity. Few women have enrolled in clinical trials of latency reversal agents (LRAs); their effectiveness in women is unknown. We hypothesized that ESR1 antagonism would augment induction of HIV expression by the LRA vorinostat. METHODS: AIDS Clinical Trials Group A5366 enrolled 31 virologically suppressed, postmenopausal women on antiretroviral therapy. Participants were randomized 2:1 to receive tamoxifen (arm A, TAMOX/VOR) or observation (arm B, VOR) for 5 weeks followed by 2 doses of vorinostat. Primary end points were safety and the difference between arms in HIV RNA induction after vorinostat. Secondary analyses included histone 4 acetylation, HIV DNA, and plasma viremia by single copy assay (SCA). RESULTS: No significant adverse events were attributed to study treatments. Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0.8; 95% confidence interval [CI], .2-2.4). Vorinostat-induced HIV transcription was higher in participants with increases in H4Ac (fold increase, 2.78; 95% CI, 1.34-5.79) vs those 9 who did not (fold increase, 1.04; 95% CI, .25-4.29). HIV DNA and SCA plasma viremia did not substantially change. CONCLUSIONS: Tamoxifen did not augment vorinostat-induced HIV RNA expression in postmenopausal women. The modest latency reversal activity of vorinostat, postmenopausal status, and low level of HIV RNA expression near the limits of quantification limited assessment of the impact of tamoxifen. This study is the first HIV cure trial done exclusively in women and establishes both the feasibility and necessity of investigating novel HIV cure strategies in women living with HIV. CLINICAL TRIALS REGISTRATION: NCT03382834.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Scully EP, Aga E, Tsibris A, et al. Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clin Infect Dis. 2022. PMID: 35176755. doi:10.1093/cid/ciac136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。